Intermediate cell type iris melanoma

Summary

Intermediate cell type iris melanoma (MONDO:0004063) is a cancer. A subtype of intermediate cell type uveal melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intermediate cell type iris melanoma
Mondo ID	MONDO:0004063
DOID	DOID:6993
NCIT	C6101
UMLS	C1334210
MedGen	233564
GARD	0023801
Anatomy (UBERON)	UBERON:0001769
Is cancer (heuristic)	yes

Also known as: Intermediate cell type iris melanoma · intermediate cell type uveal melanoma of iris · iris intermediate cell type uveal melanoma

Disease family

This is a subtype of intermediate cell type uveal melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › uveal cancer › uveal melanoma › intermediate cell type uveal melanoma › intermediate cell type iris melanoma

Related subtypes (1): intermediate cell type choroid melanoma

Subtypes (1): intermediate cell type ciliary body melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.